In clinical trials for the majority of FDA-approved cancer drugs, fewer than 5 percent of the patients were black, Stat News and ProPublica reported Wednesday.
Out of the 31 cancer drugs approved since 2015, 24 of them have had single-digit proportions of black patients during trials, the analysis found. In one trial for a multiple myeloma treatment, just 1.8 percent of participants were black, even though black Americans are twice as likely as white Americans to be diagnosed with the blood cancer and there may be "meaningful differences" in how the condition affects the two races.
The Food and Drug Administration has not established any rules that would require drug makers to test treatments on minority patients, and many manufacturers don't diversify their trials voluntarily, reports Stat News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Drug companies often say it is challenging to enroll minorities, reports ProPublica. The clinical trials with the highest black participation, up to 12 percent, were from Johnson & Johnson, a company that uses an internal group to improve trial diversity. Advocates have called on the FDA to implement similar standards across the industry, but the agency has demurred.
Minorities are also often not properly incentivized or are not able to participate: Financial barriers, logistical challenges, and distrust of the medical community are all factors that sometimes discourage minorities from joining trials, even though they could be "life-extending opportunities," said Dr. Kashif Ali, research head at Maryland Oncology Hematology. Read more at Stat News.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
What is biochar?The Explainer The charcoal alternative formed from biomass could become the next climate solution
-
Why the US needs the CROWN Act
The Explainer A Texas lawsuit has renewed discourse over race-based hair discrimination.
-
'Every parent's nightmare'
Today's Newspapers A round-up of the headlines from the UK front pages
-
Animals and plants that have been used to fight disease
The Explainer The world's flora and fauna have long been medically important
-
Heat harms the brain more than we think
Warmer temperatures could be affecting us mentally
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
-
Will Medicare drug price controls save lives?
Talking Point Medicare starts negotiating lower drug prices over Big Pharma protests
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
-
Medicare drug price negotiations start with 1st 10 drugs, pharmaceutical industry lawsuits
Speed Read
